BioAge Labs (BIOA) Citi's Biopharma Back to School Conference summary

Platform and target discovery

• Focuses on mechanisms of aging and metabolic aging using longitudinal human biobank data to identify targets for healthier aging and metabolism.

• Proprietary platform led to discovery of NLRP3 and APJ targets, with collaborations for target discovery and drug development with Novartis and Lilly.

• Ongoing partnerships expand bandwidth for target identification and asset development.

NLRP3 program and clinical development

• Lead asset BGE-102 is an oral, brain-penetrant NLRP3 inhibitor with best-in-class properties and a novel binding site.

• Preclinical data show potent weight loss as monotherapy and in combination with incretins, with brain exposure correlating to efficacy.

• Phase I SAD/MAD study underway, with key data on safety and IL-1β inhibition expected by year-end; obesity trial to start next year with three-month monotherapy design.

• Targeting semaglutide-like weight loss, with potential for combination therapy to achieve tirzepatide-like results.

• Asset may address comorbidities such as cardiovascular disease and osteoarthritis.

APJ program and pipeline expansion

• Advancing oral small molecules and a nanobody agonist for APJ, aiming for IND filings next year.

• APJ mechanism shown to preserve muscle in older populations and is additive to appetite-suppressing drugs.

• Both oral and long-acting injectable formats in development, with potential for monthly dosing for the nanobody.

• Pipeline could have three clinical assets next year, with ongoing early-stage work and collaborations to identify new targets.